PriceTargets.com logo

Phreesia - PHR Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $37.15
  • Forecasted Upside: 104.70%
  • Number of Analysts: 13
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$18.15 As of 09/21/2023 01:00 AM ET
▼ -0.7 (-3.71%)

This chart shows the closing price for PHR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Phreesia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PHR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PHR

Analyst Price Target is $37.15
▲ +104.70% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Phreesia in the last 3 months. The average price target is $37.15, with a high forecast of $43.00 and a low forecast of $29.00. The average price target represents a 104.70% upside from the last price of $18.15.

This chart shows the closing price for PHR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 13 polled investment analysts is to moderate buy stock in Phreesia. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/12/2023Piper SandlerLower TargetOverweight ➝ Overweight$43.00 ➝ $40.00Low
9/11/2023Raymond JamesLower TargetOutperform ➝ Outperform$40.00 ➝ $30.00Low
9/7/2023William BlairReiterated RatingOutperformLow
9/7/2023Canaccord Genuity GroupLower TargetBuy ➝ Buy$46.00 ➝ $43.00Low
9/7/2023Needham & Company LLCReiterated RatingBuy ➝ Buy$40.00Low
9/7/2023StephensReiterated RatingOverweight ➝ Overweight$37.00Low
9/7/2023Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$33.00 ➝ $29.00Low
9/7/2023CitigroupLower TargetBuy ➝ Buy$40.00 ➝ $37.00Low
9/7/2023Robert W. BairdLower Target$40.00 ➝ $39.00Low
9/1/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$46.00Low
8/15/2023StephensReiterated RatingOverweight ➝ Overweight$37.00Low
6/2/2023Robert W. BairdLower Target$41.00 ➝ $40.00Low
5/25/2023KeyCorpLower Target$45.00 ➝ $40.00Low
4/11/2023StephensInitiated CoverageOverweight$37.00Low
3/29/2023GuggenheimBoost TargetBuy$35.00 ➝ $40.00Low
3/23/2023DA DavidsonBoost TargetNeutral$28.00 ➝ $30.00Low
3/23/2023Royal Bank of CanadaBoost TargetSector Perform$26.00 ➝ $33.00Low
3/23/2023JMP SecuritiesBoost TargetOutperform$34.00 ➝ $39.00Low
2/2/2023KeyCorpBoost TargetOverweight$40.00 ➝ $45.00Low
1/25/2023Piper SandlerBoost TargetOverweight$37.00 ➝ $43.00Low
1/5/2023SVB LeerinkBoost TargetOutperform$34.00 ➝ $39.00Low
1/4/2023Needham & Company LLCBoost TargetBuy$35.00 ➝ $40.00Low
12/14/2022Robert W. BairdBoost Target$41.00Low
12/13/2022CitigroupUpgradeNeutral ➝ Buy$40.00Low
12/9/2022Royal Bank of CanadaBoost TargetSector Perform$22.00 ➝ $26.00Low
12/9/2022Piper SandlerBoost Target$33.00 ➝ $37.00Low
12/9/2022DA DavidsonBoost Target$25.00 ➝ $28.00Low
12/9/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$31.00 ➝ $34.00Low
12/9/2022CitigroupBoost Target$25.00 ➝ $28.00Low
10/12/2022DA DavidsonInitiated CoverageNeutral$25.00Low
9/15/2022KeyCorpInitiated CoverageOverweight$40.00Low
9/8/2022Canaccord Genuity GroupLower TargetBuy$37.00 ➝ $36.00Low
9/8/2022Royal Bank of CanadaBoost TargetSector Perform$20.00 ➝ $22.00Low
9/8/2022GuggenheimBoost TargetBuy$30.00 ➝ $35.00Low
9/8/2022CitigroupBoost Target$23.00 ➝ $25.00Low
9/8/2022SVB LeerinkBoost TargetMarket Perform$27.00 ➝ $31.00Low
6/14/2022Piper SandlerLower TargetOverweight$42.00 ➝ $32.00Medium
6/6/2022Royal Bank of CanadaLower Target$29.00 ➝ $20.00Low
6/6/2022Raymond JamesLower Target$45.00 ➝ $34.00Low
6/3/2022GuggenheimLower TargetBuy$45.00 ➝ $30.00High
6/3/2022Robert W. BairdLower TargetOutperform$51.00 ➝ $35.00High
6/3/2022JMP SecuritiesLower TargetMarket Outperform$50.00 ➝ $34.00High
6/3/2022CitigroupLower TargetNeutral$36.00 ➝ $23.00High
6/3/2022SVB LeerinkLower TargetMarket Perform$29.00 ➝ $22.00High
4/13/2022GuggenheimInitiated CoverageBuy$45.00High
4/7/2022Royal Bank of CanadaLower TargetSector Perform$51.00 ➝ $29.00High
4/4/2022Piper SandlerLower Target$54.00 ➝ $42.00Low
4/1/2022Raymond JamesLower TargetOutperform$55.00 ➝ $45.00High
3/31/2022Canaccord Genuity GroupLower TargetBuy$81.00 ➝ $49.00High
3/31/2022JPMorgan Chase & Co.Lower Target$51.00 ➝ $42.00High
3/31/2022SVB LeerinkLower TargetMarket Perform$41.00 ➝ $29.00High
3/31/2022Needham & Company LLCLower TargetBuy$65.00 ➝ $35.00High
3/31/2022JMP SecuritiesLower TargetMarket Outperform$70.00 ➝ $50.00High
3/31/2022CitigroupLower TargetNeutral$54.00 ➝ $36.00High
1/6/2022SVB LeerinkDowngradeOutperform ➝ Market Perform$57.00 ➝ $41.00High
12/14/2021Raymond JamesLower TargetOutperform ➝ Outperform$75.00 ➝ $55.00Medium
12/14/2021Piper SandlerLower TargetOverweight ➝ Overweight$69.00 ➝ $54.00Medium
12/10/2021CitigroupLower TargetNeutral ➝ Neutral$72.00 ➝ $54.00High
12/10/2021SVB LeerinkLower TargetOutperform$75.00 ➝ $57.00High
12/9/2021Needham & Company LLCLower TargetBuy ➝ Buy$81.00 ➝ $65.00High
12/9/2021Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$60.00 ➝ $51.00High
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$70.00High
9/7/2021Berenberg BankReiterated RatingBuy$75.00Medium
9/3/2021Raymond JamesBoost TargetOutperform$65.00 ➝ $75.00High
9/3/2021Robert W. BairdBoost TargetOutperform$62.00 ➝ $67.00High
9/2/2021Royal Bank of CanadaBoost TargetSector Perform$51.00 ➝ $60.00High
9/2/2021Needham & Company LLCBoost TargetBuy$70.00 ➝ $81.00High
7/13/2021JMP SecuritiesInitiated CoverageOutperform$80.00High
7/12/2021KeyCorpBoost TargetOverweight$70.00 ➝ $73.00High
6/17/2021JPMorgan Chase & Co.Boost TargetOverweight$64.00 ➝ $68.00Medium
6/8/2021Berenberg BankInitiated CoverageBuy$70.00High
6/7/2021Robert W. BairdBoost TargetOutperform$60.00 ➝ $62.00High
6/7/2021Piper SandlerBoost TargetOverweight$58.00 ➝ $63.50High
6/6/2021SVB LeerinkReiterated RatingBuyHigh
4/29/2021JPMorgan Chase & Co.Initiated CoverageOverweightLow
4/1/2021SVB LeerinkLower TargetOutperform$85.00 ➝ $75.00High
4/1/2021Robert W. BairdInitiated CoverageOutperform$60.00High
3/31/2021Piper SandlerReiterated RatingOverweight$56.00 ➝ $58.00High
3/31/2021KeyCorpLower TargetOverweight$80.00 ➝ $70.00Low
1/14/2021Needham & Company LLCBoost TargetBuy$60.00 ➝ $70.00High
12/14/2020Smith Barney CitigroupBoost Target$33.00 ➝ $59.00Low
12/10/2020Royal Bank of CanadaBoost TargetSector Perform$33.00 ➝ $51.00High
12/10/2020DA DavidsonBoost TargetBuy$35.00 ➝ $70.00High
12/10/2020SVB LeerinkBoost TargetOutperform$37.00 ➝ $62.00High
12/9/2020Piper SandlerBoost TargetOverweight$35.00 ➝ $56.00High
12/9/2020Needham & Company LLCBoost TargetBuy$44.00 ➝ $60.00Medium
12/4/2020KeyCorpBoost TargetOverweight$37.00 ➝ $50.00High
11/10/2020StephensInitiated CoverageOverweight$50.00Medium
10/27/2020Needham & Company LLCInitiated CoverageBuy$44.00Low
10/23/2020Robert W. BairdBoost TargetPositive ➝ Outperform$32.00 ➝ $44.00Low
9/22/2020DA DavidsonInitiated CoverageBuy$35.00Low
9/10/2020Raymond JamesBoost TargetOutperform$35.00 ➝ $36.00High
9/10/2020SVB LeerinkBoost TargetOutperform$31.00 ➝ $37.00Medium
9/9/2020Piper SandlerBoost TargetOverweight$34.00 ➝ $35.00Medium
9/3/2020Raymond JamesReiterated RatingBuyLow
7/14/2020CitigroupInitiated CoverageNeutral$32.00Low
6/10/2020Raymond JamesBoost TargetOutperform$30.00 ➝ $35.00High
6/9/2020KeyCorpBoost TargetOverweight$34.00 ➝ $37.00High
5/20/2020KeyCorpBoost TargetOverweight$25.00 ➝ $34.00High
5/15/2020GuggenheimInitiated CoverageBuy$31.00Medium
4/24/2020Raymond JamesLower TargetOutperform$33.00 ➝ $30.00Low
4/24/2020Robert W. BairdBoost TargetOutperform$26.00 ➝ $28.00Low
4/24/2020Wells Fargo & CompanyLower TargetOverweight$35.00 ➝ $30.00High
4/20/2020Royal Bank of CanadaInitiated CoverageSector Perform$21.00Low
4/13/2020SVB LeerinkInitiated CoverageOutperform$24.00Medium
4/8/2020Robert W. BairdLower TargetOutperform$31.00 ➝ $26.00High
3/31/2020KeyCorpLower TargetOverweight$36.00 ➝ $25.00High
1/30/2020KeyCorpInitiated CoverageOverweight$36.00Low
1/8/2020Cantor FitzgeraldInitiated CoverageOverweight$32.00Medium
12/19/2019Raymond JamesInitiated CoverageOutperform$33.00Low
10/10/2019Robert W. BairdInitiated CoverageOutperform$31.00High
9/10/2019Piper Jaffray CompaniesSet TargetBuy$33.00Low
8/13/2019JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$33.00Low
8/12/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$23.00High
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$33.00High
8/12/2019William BlairInitiated CoverageOutperform ➝ OutperformHigh
7/23/2019Chardan CapitalInitiated CoverageBuy ➝ Buy$33.00Low
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2023
  • 10 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2023
  • 7 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2023
  • 8 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
6/23/2023
  • 7 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2023
  • 6 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2023
  • 14 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023

Current Sentiment

  • 14 very positive mentions
  • 16 positive mentions
  • 5 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Phreesia logo
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, a self-service intake tablets; and Arrivals Kiosks, an on-site kiosks. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Wilmington, Delaware.
Read More

Today's Range

Now: $18.15
Low: $18.04
High: $18.82

50 Day Range

MA: $27.67
Low: $18.85
High: $33.75

52 Week Range

Now: $18.15
Low: $18.04
High: $40.00

Volume

527,122 shs

Average Volume

417,425 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63

Frequently Asked Questions

What sell-side analysts currently cover shares of Phreesia?

The following sell-side analysts have issued stock ratings on Phreesia in the last twelve months: Canaccord Genuity Group Inc., Citigroup Inc., DA Davidson, Guggenheim, JMP Securities, KeyCorp, Needham & Company LLC, Piper Sandler, Raymond James, Robert W. Baird, Royal Bank of Canada, Stephens, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for PHR.

What is the current price target for Phreesia?

13 Wall Street analysts have set twelve-month price targets for Phreesia in the last year. Their average twelve-month price target is $37.15, suggesting a possible upside of 102.3%. Canaccord Genuity Group Inc. has the highest price target set, predicting PHR will reach $43.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $29.00 for Phreesia in the next year.
View the latest price targets for PHR.

What is the current consensus analyst rating for Phreesia?

Phreesia currently has 2 hold ratings and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for PHR.

What other companies compete with Phreesia?

Other companies that are similar to Phreesia include MultiPlan, American Well, Tabula Rasa HealthCare, Ligand Pharmaceuticals and Acelyrin. Learn More about companies similar to Phreesia.

How do I contact Phreesia's investor relations team?

Phreesia's physical mailing address is 432 Park Avenue South 12th Floor, New York NY, 10016. The company's listed phone number is (888) 654-7473 and its investor relations email address is [email protected]. The official website for Phreesia is www.phreesia.com. Learn More about contacing Phreesia investor relations.